Safety and Efficacy of Periprocedural Anticoagulation With Enoxaparin in Patients Undergoing Peripheral Endovascular Revascularization

Brodmann, Marianne; Dorr, Andreas; Hafner, Franz; Tse, Gary; Froehlich, Harald; Kvas, Erich; Deutschmann, Hannes; Pilger, Ernst

doi:10.1177/1076029613492877

Cited by 3 publications

(2 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The use of Enoxaparin instead of unfractionated heparin is standard procedure in our department and seems to be safe with regards to complications of peripheral vascular interventions (26,27). Due to its superior handling in clinical routine as well as the avoidance of heparin induced thrombocytopenia type II, this procedure is generally accepted and did not influence our results.…”

Section: Discussionmentioning

confidence: 81%

Exoseal for puncture site closure after antegrade procedures in peripheral arterial disease patients

Hackl

Tse²,

Belaj³

et al. 2014

Diagn Interv Radiol

Self Cite

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 81%

Exoseal for puncture site closure after antegrade procedures in peripheral arterial disease patients

Hackl

Tse²,

Belaj³

et al. 2014

Diagn Interv Radiol

Self Cite

View full text Add to dashboard Cite

“…Its anticoagulant properties and longer half-life make it applicable to peripheral arterial intervention, especially in the periprocedural setting. 25 There are no large-scale trials examining the use of LMWH for the prevention of restenosis or adverse events after arterial intervention. However, Duschek et al examined the use of enoxaparin periprocedurally in comparison to heparin in patients undergoing peripheral arterial interventions.…”

Section: Low-molecular-weight Heparinmentioning

confidence: 99%

Anticoagulation and Antiplatelet Agents in Peripheral Arterial Interventions

Taylor

Stiepel

Keefe

2022

Semin intervent Radiol

View full text Add to dashboard Cite

Effective revascularization of peripheral artery disease relies on periprocedural pharmacological regulation of the clotting cascade. Patient-specific factors such as cardiovascular risk factors, contraindications, and individual psychosocial factors must be considered when initiating post revascularization management. Management with anticoagulant and antiplatelet agents is discussed to guide the interventionalist on which therapy may be appropriate for their patient. While exact treatment may be institution and provider dependent, the interventionist must be familiar with the available classes of medications and how they can be prescribed in the postprocedural setting to improve cardiovascular outcomes.

show abstract

Anticoagulation in Peripheral Artery Disease: Are We There Yet?

Cannavale

Santoni

Cannavale

et al. 2020

Vascular and Endovascular Review

View full text Add to dashboard Cite

Thromboembolism in patients with peripheral artery disease (PAD) represents a common cause of morbidity and mortality. In this article, the authors analyse the use of anticoagulants for patients with PAD. Anticoagulants have been used to reduce the risk of venous thromboembolism, but have recently been applied to the arterial circulation. Heparins were introduced to reduce short-term major adverse limb events in patients undergoing arterial revascularisation. Low molecular weight heparins have allowed easier management and carry a lower risk of bleeding than unfractioned heparin. Vitamin K anticoagulants have been tested in trials that included patients with PAD, showing an increased risk of bleeding when compared with aspirin alone, but longer patency rates for venous surgical bypass, although the evidence remains weak. Those anticoagulants are currently recommended only in patients with PAD who need anticoagulation for other diseases. Direct oral anticoagulants have only recently been investigated for use in patients with PAD. Promising results from low dose rivaroxaban plus aspirin have been recently outlined by a randomised controlled trial and supported by international guidelines.

show abstract

Safety and Efficacy of Periprocedural Anticoagulation With Enoxaparin in Patients Undergoing Peripheral Endovascular Revascularization

Cited by 3 publications

References 19 publications

Exoseal for puncture site closure after antegrade procedures in peripheral arterial disease patients

Exoseal for puncture site closure after antegrade procedures in peripheral arterial disease patients

Anticoagulation and Antiplatelet Agents in Peripheral Arterial Interventions

Anticoagulation in Peripheral Artery Disease: Are We There Yet?

Contact Info

Product

Resources

About